 | Up a level |
Galling, B; Roldán, A; Hagi, K; Rietschel, L; Walyzada, F; Zheng, W; Cao, XL; Xiang, YT; Zink, M; Kane, JM; Nielsen, J; Leucht, S; Correll, CU (2017). Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World psychiatry, 16(1), pp. 77-89. Wiley 10.1002/wps.20387
Galling, B; Roldán, A; Rietschel, L; Hagi, K; Walyzada, F; Zheng, W; Cao, XL; Xiang, YT; Kane, JM; Correll, CU (2016). Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opinion on Drug Safety, 15(5), pp. 591-612. Taylor & Francis 10.1517/14740338.2016.1165668
Lo Cascio, N; Saba, R; Hauser, M; Vernal, DL; Al-Jadiri, A; Borenstein, Y; Sheridan, EM; Kishimoto, T; Armando, M; Vicari, S; Fiori Nastro, P; Girardi, P; Gebhardt, E; Kane, JM; Auther, A; Carrión, RE; Cornblatt, BA; Schimmelmann, BG; Schultze-Lutter, F and Correll, CU (2016). Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. European child & adolescent psychiatry, 25(10), pp. 1091-1102. Springer 10.1007/s00787-016-0832-7
